## Product Datasheet

# Quilseconazole

Catalog No. **BP-01871** · CAS **1340593-70-5** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-07**

**FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.**

| Target | Research area |
|---|---|
| **Fungal; Cytochrome P450** | **Infection; Inflammation/Immunology** |

| | |
|---|---|
| Molecular formula | $C_{22}H_{14}F_7N_5O_2$ |
| Molecular weight | **513.3677** |

**STRUCTURE**



## DESCRIPTION

Quilseconazole (VT-1129) is a potent, orally active fungal Cyp51 (lanosterol 14-α-demethylase) inhibitor, binds tightly to cryptococcal CYP51, but weakly inhibits humans CYP450 enzymes.

## BIOLOGICAL ACTIVITY

Quilseconazole exhibits potent antifungal activity against Cryptococcus neoformans and Cryptococcus gattii VT-1129 (0.15-30 mg/kg; oral gavage; 10-14 days) shows antifungal activity in a mouse model of cryptococcal meningitis Pharmacokinetic Analysis inMale CD-1 Mice

## SOLUBILITY

Soluble in DMSO : 100 mg/mL

## REFERENCES

[1]. Lockhart SR, et al. The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2528-31.

[2]. Wiederhold NP, et al. In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01315-18.

[3]. Warrilow AG, et al. The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4530-8.